I suppose it’s time to get behind them and face the facts that it’s better they get into the clinic than pontificate and navel gaze.
But the coy needs to build out clinical capability and own it. That can’t reside in a Chairman’s role.
I truly thank Mark for his dedication and perseverance. But after 20 + years I ask for an orderly transition to bring forward the capability the company needs.
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-87
-
- There are more pages in this discussion • 265 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $99.16M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 10.5¢ | $165.6K | 1.517M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 527880 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 387554 | 5 |
View Market Depth
| Last trade - 11.59am 30/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |